At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Trading 01-13 11:14:55 EST
0.8750
-0.0300
-3.31%
High0.8925Low0.8700Vol71.85K
Open0.8779D1 Closing0.9050Amplitude2.49%
Mkt Cap20.20MTradable Cap16.20MTotal Shares23.09M
T/O63.11KT/O Rate0.39%Tradable Shares18.52M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer
Reuters  ·  01-13 20:02
Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer
Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026
THOMSON REUTERS  ·  01-13 20:01
Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
GlobeNewswire  ·  01-13 20:01
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1
Reuters  ·  01-12 12:26
Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1
Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders
Reuters  ·  2025-12-20
Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders
Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-12-08
Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target
MT Newswires Live  ·  2025-12-08
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target
Pasithea Therapeutics Corp. : H.c. Wainwright Initiates Coverage With Buy Rating
THOMSON REUTERS  ·  2025-12-08
Pasithea Therapeutics Corp. : H.c. Wainwright Initiates Coverage With Buy Rating
Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Dow Jones  ·  2025-12-02
Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.
Filings Track  ·  2025-12-01
Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.
Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares
Reuters  ·  2025-12-01
Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares
Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares
Reuters  ·  2025-12-01
Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares
US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong
MT Newswires Live  ·  2025-11-29
US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong
Top Midday Gainers
MT Newswires Live  ·  2025-11-29
Top Midday Gainers
Crude Oil Gains 1%; Tilray Brands Shares Plunge
Benzinga  ·  2025-11-29
Crude Oil Gains 1%; Tilray Brands Shares Plunge
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Reuters  ·  2025-11-28
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Pasithea Therapeutics prices 80M shares at 75c in public offering
TIPRANKS  ·  2025-11-28
Pasithea Therapeutics prices 80M shares at 75c in public offering
Pasithea Therapeutics Corp - Cash Position to Extend Runway Through First Half of 2028
THOMSON REUTERS  ·  2025-11-28
Pasithea Therapeutics Corp - Cash Position to Extend Runway Through First Half of 2028
Pasithea Therapeutics Corp - Prices Public Offering of 80 Mln Shares at $0.75 Each
THOMSON REUTERS  ·  2025-11-28
Pasithea Therapeutics Corp - Prices Public Offering of 80 Mln Shares at $0.75 Each
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
GlobeNewswire  ·  2025-11-28
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Introduction

Company Name.
Pasithea Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Issue price:
--